Updated on 12 May 2015
The MoU is expected to pave way for the export of CHA Health Systems' infertility treatment to the Japanese market
Singapore: South Korea-based global healthcare enterprise, CHA Health Systems has inked a pact with Japanese medical corporation Otsubo-Kai to develop new cell therapies and conduct joint research on regenerative medicine including stem cells and immune cells.
The MoU is expected to pave way for the export of CHA Health Systems' infertility treatment to the Japanese market and will give an impetus to Tokyo Cell Clinic (TCC), CHA Health Systems' Japanese unit.
Under the deal, both companies will exchange biotechnology personnel, resident physicians, professors, health examination systems and will conduct seminars and symposiums.
"I was inspired by CHA Health Systems' progress in regenerative medicine research and infertility treatment and by its novel hospital model ‘Chaum.' I believe that our tie-up with CHA Health Systems would breathe new life into the Japanese healthcare industry," said Mr Osamu Otsubo, chairman of Otsubokai's board of directors.
Founded last year, Tokyo Cell Clinic has successfully penetrated the Japanese market, backed by its cutting-edge medical services related to cell therapy, anti-aging treatment and genomes.
Tokyo Cell Clinic specializes in immunotherapy and anti-aging treatment, which are considered the most state-of-the-art medical fields in Japan. The clinic has been running a cutting-edge in-house Cell Processing Center (CPC) in Japan that lives up to the international standards for medical treatment.